ABSTRACT
Vascular, cardiovascular and neurovascular ageing processes contribute to cognitive impairment. However, the unique and synergistic contributions of cardiovascular factors to cognitive function remain unclear because they are often condensed into a single composite score or examined in isolation of each other. We hypothesized that vascular risk factors, electrocardiographic features and blood pressure indices reveal multiple latent vascular factors, with independent contributions to age differences in cognition. In a population-based deep-phenotyping study of cognition across the lifespan (n=708, age 18-88), path analysis revealed three latent vascular factors dissociating the autonomic nervous system response from two components of blood pressure. These three factors made unique and additive contributions to the variability in crystallized and fluid intelligence. The discrepancy in fluid relative to crystallized intelligence, indicative of cognitive decline, was associated with a latent vascular factor predominantly expressing pulse pressure, suggesting that higher pulse pressure is associated with cognitive decline from expected performance. This association varied with age, such that higher factor scores predicted a greater cognitive discrepancy in older individuals. Controlling pulse pressure may help to preserve cognitive function, particularly in older adults. Our findings highlight the need to better understand the multifactorial nature of vascular aging, its effects on neurocognitive function, and the modifiable risks of cognitive decline.
Competing Interest Statement
All authors have no conflicts of interest. Unrelated to this, there are several disclosures: Cam-CAN was supported by the Biotechnology and Biological Sciences Research Council Grant BB/H008217/1. D.L.O.K. was supported by a Doctoral Training Programme studentship awarded by the Biotechnology and Biological Sciences Research Council (BBSRC BB/M011194/1) K.A.T. was supported by the Guarantors of Brain (G101149). R.N.A.H. was supported by the UK Medical Research Council (SUAG/046 G101400). J.B.R. was supported by the UK Medical Research Council (SUAG/051 G101400) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014; The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care) and Wellcome Trust (220258). J.B.R. serves as an associate editor to Brain and is 518 a non-remunerated trustee of the Guarantors of Brain, Darwin College and the PSP Association (UK). He provides consultancy to Asceneuron, Biogen, UCB and has research grants from AZ-Medimmune, Janssen, and Lilly as industry partners in the Dementias Platform UK. We thank the Cam-CAN respondents and their primary care teams in Cambridge for their participation in this study, and colleagues at the MRC Cognition and Brain Sciences Unit MEG and MRI facilities for their assistance. Further information about the Cam-CAN corporate authorship membership can be found at http://www.cam-can.com/publications/Cam-CAN_Corporate_Author.html (list #13).
Funding Statement
Cam-CAN was supported by the Biotechnology and Biological Sciences Research Council Grant BB/H008217/1. D.L.O.K. was supported by a Doctoral Training Programme studentship awarded by the Biotechnology and Biological Sciences Research Council (BBSRC BB/M011194/1) K.A.T. was supported by the Guarantors of Brain (G101149). R.N.A.H. was supported by the UK Medical Research Council (SUAG/046 G101400). J.B.R. was supported by the UK Medical Research Council (SUAG/051 G101400) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014; The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care) and Wellcome Trust (220258). We thank the Cam-CAN respondents and their primary care teams in Cambridge for their participation in this study, and colleagues at the MRC Cognition and Brain Sciences Unit MEG and MRI facilities for their assistance. Further information about the Cam-CAN corporate authorship membership can be found at http://www.cam-can.com/publications/Cam-CAN_Corporate_Author.html (list #13).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Cambridgeshire 2 (now East of England Cambridge Central) Research Ethics Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data analysed in the present study can be requested from the Cambridge Centre for Ageing and Neuroscience (Cam-CAN).
